Dowsett M

No ORCID on file · 13 papers in corpus · active 1984-2017

Study types

  • article 7
  • letter 1
  • other 1
  • rct 1

Condition tags

  • endometriosis 10
  • dysmenorrhea 1
  • dyspareunia 1
2017
Cancer causes & control : CCC ·doi:10.1007/s10552-017-0971-2

PurposeMenstrual cycle characteristics are markers of endocrine milieu. However, associations between age at menarche and adulthood sex steroid hormone levels have been inconsistent, and data on menstrual characteristics and non-sex steroid…

article 1995
Clinical endocrinology ·doi:10.1111/j.1365-2265.1995.tb02926.x

OBJECTIVE: GnRH analogues are being used increasingly for a number of oestrogen dependent conditions in women. The resultant profound hypo-oestrogenism is a disadvantage, however, but the preservation of pituitary sensitivity to negative fe…

rct 1995
Fertility and Sterility ·doi:10.1016/s0015-0282(16)57779-6

OBJECTIVE: To determine whether treatment of endometriosis with a GnRH analogue (GnRH-a; goserelin) combined with continuous estrogen and progestogen hormone replacement therapy (HRT) would prevent the hypoestrogenic effects, including loss…

article 1994
Human Reproduction ·doi:10.1093/oxfordjournals.humrep.a138788

The expression of receptors for the ovarian steroid hormones oestrogen and progesterone was studied immunohistochemically using monoclonal antibodies in samples of endometriosis and endometrium in 22 patients. In nine patients samples of en…

1993
British journal of cancer ·doi:10.1038/bjc.1993.69

Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocarcinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 milligrams twice daily was commenced with th…

article 1991
Fertility and Sterility ·doi:10.1016/s0015-0282(16)54294-0

ObjectiveTo determine whether the effect of danazol on gonadotropin pulsatility was due to a direct effect of the drug or the suppression in the estradiol (E2) levels.DesignProspective analysis of serial blood samples at 10-minute intervals…

1990
British journal of cancer ·doi:10.1038/bjc.1990.388

Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrog…

article 1990
Clinical endocrinology ·doi:10.1111/j.1365-2265.1990.tb03891.x

SUMMARY In an attempt to determine whether the suppression in oestradiol levels caused by danazol is due to an effect on the hypothalamic‐pituitary axis, we compared the endocrine effects of danazol with those of the LHRH (GnRH) agonist ana…

letter 1989
Lancet (London, England) ·doi:10.1016/s0140-6736(89)92659-7
other 1988
Fertility and Sterility ·doi:10.1016/s0015-0282(16)59706-4

Danazol and gestrinone are effective drugs in the treatment of endometriosis. Their mechanism of action remains uncertain, but may be related to their androgenic activity. The authors examined the effect of danazol on human endometrial cell…

article 1986
Clinical endocrinology ·doi:10.1111/j.1365-2265.1986.tb03285.x

Danazol and gestrinone are both effective agents in the treatment of endometriosis. Their mechanism of action is unknown but may be related to their androgenic activity, which is at least partly dependent on increases in the proportion of t…

article 1986
Clinical endocrinology ·doi:10.1111/j.1365-2265.1986.tb03614.x

Danazol is known to cause marked suppression of sex hormone binding globulin (SHBG) levels in plasma and to increase the proportion of plasma testosterone unbound to protein but the effect on the concentration of total and free testosterone…

article 1984
British journal of obstetrics and gynaecology ·doi:10.1111/j.1471-0528.1984.tb05901.x

The effects of danazol therapy on circulating gonadotrophins, oestradiol and sex hormone-binding globulin (SHBG) binding capacity have been studied in eight patients with endometriosis. There was a significant rise in luteinizing hormone (L…